Key result
Positive airway pressure therapy initiation was associated with a lower risk of all-cause mortality and major adverse cardiovascular events in older adults with OSA.
Why the study?
PAP is the first-line treatment for OSA, but evidence on its beneficial effect on MACE prevention is limited.
Does positive airway pressure therapy initiation and utilization reduce mortality and major adverse cardiovascular events in older adults with obstructive sleep apnea?
Observational (n=225,132)
Does positive airway pressure therapy initiation and utilization reduce mortality and major adverse cardiovascular events in older adults with obstructive sleep apnea?
Answers are grounded in this paper and cite their sources.
In a large cohort of Medicare beneficiaries with obstructive sleep apnea, initiation and higher utilization of positive airway pressure therapy were associated with significantly lower risks of all-cause mortality and major adverse cardiovascular events.
Background: Obesity is associated with obstructive sleep apnea (OSA) and cardiovascular risk. Positive airway pressure (PAP) is the first line treatment for OSA, but evidence on its beneficial effect on major adverse cardiovascular events (MACE) prevention is limited. Using claims data, the effects of PAP on mortality and incidence of MACE among Medicare beneficiaries with OSA were examined. Methods: A cohort of Medicare beneficiaries with ≥2 distinct OSA claims was defined from multi-state, state-wide, multi-year (2011-2020) Medicare fee-for-service claims data. Evidence of PAP initiation and utilization was based on PAP claims after OSA diagnosis. MACE was defined as a composite of myocardial infarction, heart failure, stroke, or coronary revascularization. Doubly robust Cox proportional hazards models with inverse probability of treatment weights estimated treatment effects controlling for sociodemographic and clinical factors. Results: Among 888,835 beneficiaries with OSA (median age 73 years; 43.9% women; median follow-up 1,141 days), those with evidence of PAP initiation (32.6%) had significantly lower all-cause mortality (HR [95%CI]: 0.53 [0.52-0.54]) and MACE incidence risk (0.90 [0.89-0.91]). Higher quartiles of annual PAP claims were progressively associated with lower mortality (Q2: 0.84 [0.81-0.87], Q3: 0.76 [0.74-0.79], Q4: 0.74 [0.72-0.77]) and MACE incidence risk (Q2: 0.92 [0.89-0.95], Q3: 0.89 [0.86-0.91], Q4: 0.87 [0.85-0.90]). Conclusion: PAP utilization was associated with lower all-cause mortality and MACE incidence among Medicare beneficiaries with OSA. Results might inform trials assessing the importance of OSA therapy towards minimizing cardiovascular risk and mortality in older adults.
No takes yet. Share an insight, caveat, or question.
Mazzotti et al. (2023) conducted an observational in Obstructive Sleep Apnea (n=225,132). Positive Airway Pressure (PAP) therapy vs. No PAP therapy initiation was evaluated on All-cause mortality (HR 0.57, 95% CI 0.56-0.59, p=<0.001). Positive airway pressure therapy initiation was associated with a lower risk of all-cause mortality and major adverse cardiovascular events in older adults with OSA.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: